Literature DB >> 29901009

A Case of Primary Sjögren's Syndrome Presenting as Mass-Like Encephalitis, With Progression to Neuromyelitis Optica Spectrum Disorder.

Hyun-Jung Lee1, Sung Hae Chang2, Eun Ha Kang3, Yun Jong Lee3, Yeong Wook Song4, You-Jung Ha3.   

Abstract

Neuromyelitis optica is an idiopathic inflammatory demyelinating disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. With the discovery of the pathogenic anti-aquaporin-4 (AQP4) antibody, the disease was recognized as part of a spectrum of autoimmune diseases that target AQP4, collectively referred to as neuromyelitis optica spectrum disorder (NMOSD). NMOSD consists of conditions that affect various parts of the CNS with the AQP4 antibody. In this article, we report a 43-year-old female patient who was initially diagnosed with primary Sjögren's syndrome (pSS) with CNS involvement, but was later diagnosed with overlapping pSS and NMOSD, which required more intensive treatment. The patient presented with fever, headache, dysarthria, and left-side weakness, and brain imaging showed a mass-like edematous lesion in the right frontoparietal region. She also complained of xerostomia and was diagnosed with pSS by salivary scintigraphy, anti-Sjögren's syndrome A positivity, and minor salivary gland biopsy. Under the diagnosis of pSS with CNS involvement in the form of tumefactive encephalitis, she was treated with high-dose steroids and monthly intravenous cyclophosphamide therapy. However, three months later, she developed a sudden decrease in right visual acuity and had right optic neuritis. Her serum was positive for the anti-AQP4 antibody, and she was finally diagnosed with overlapping NMOSD and pSS. She was treated with steroid pulse therapy and plasmapheresis. Therefore, in patients with pSS presenting with cerebral white matter lesions, even when optic neuritis or myelitis is absent, evaluations for the anti-AQP4 antibody should be considered to detect and treat NMOSD accordingly.

Entities:  

Keywords:  Neuromyelitis optica spectrum disorder; Sjögren’s syndrome; tumefactive encephalitis

Year:  2017        PMID: 29901009      PMCID: PMC5868465          DOI: 10.5606/ArchRheumatol.2017.6201

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  18 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease.

Authors:  Dean M Wingerchuk; Brian G Weinshenker
Journal:  Mult Scler       Date:  2011-12-06       Impact factor: 6.312

3.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 4.  Childhood Sjögren syndrome presenting as acute brainstem encephalitis.

Authors:  Yoriko Matsui; Toshiki Takenouchi; Atsushi Narabayashi; Kentaro Ohara; Tadaki Nakahara; Takao Takahashi
Journal:  Brain Dev       Date:  2015-05-23       Impact factor: 1.961

Review 5.  Neurological manifestations of primary Sjogren's syndrome.

Authors:  Josiah Chai; Eric L Logigian
Journal:  Curr Opin Neurol       Date:  2010-10       Impact factor: 5.710

6.  Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren's syndrome.

Authors:  J Michelle Kahlenberg
Journal:  Semin Arthritis Rheum       Date:  2010-07-23       Impact factor: 5.532

7.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

8.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

9.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

Review 10.  Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature.

Authors:  Apoorva Jayarangaiah; Rahul Sehgal; Narendranath Epperla
Journal:  BMC Neurol       Date:  2014-10-09       Impact factor: 2.474

View more
  3 in total

Review 1.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.

Authors:  Roberto A Cruz; Sana Chaudhary; Myriam Guevara; Ethan Meltzer
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

2.  Rheumatoid arthritis with aquaporin-4 antibody-positive neuromyelitis optica receiving rituximab therapy.

Authors:  Chrong Reen Wang; Sheng-Min Hsu; Ying-Chen Chen
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.007

3.  The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.

Authors:  Xiaofei Wang; Ziyan Shi; Zhengyang Zhao; Hongxi Chen; Yanlin Lang; Lingyao Kong; Xue Lin; Qin Du; Jiancheng Wang; Hongyu Zhou
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.